[{"id":"a3f2cdb8-5f51-4d49-bdd8-408b76b63c70","acronym":"ZANGEA","url":"https://clinicaltrials.gov/study/NCT07176312","created_at":"2025-09-20T07:08:39.876Z","updated_at":"2025-09-20T07:08:39.876Z","phase":"Phase 2","brief_title":"Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","source_id_and_acronym":"NCT07176312 - ZANGEA","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-09-16"},{"id":"fb5a3d64-2b8f-44c4-84f0-e927e52ab2a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04939051","created_at":"2024-02-29T18:31:43.001Z","updated_at":"2025-02-25T13:35:51.854Z","phase":"Phase 2","brief_title":"Obeticholic Acid for Prevention in Barrett's Esophagus","source_id_and_acronym":"NCT04939051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FGF19 • SOX2 • CASP3 • FGF • CDX2","pipe":"","alterations":" ","tags":["FGF19 • SOX2 • CASP3 • FGF • CDX2"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 09/29/2025","primary_completion_date":" 09/29/2025","study_txt":" Completion: 09/29/2026","study_completion_date":" 09/29/2026","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"cb7ed592-cf61-416e-86bf-22b417e0e5af","acronym":"M21-404","url":"https://clinicaltrials.gov/study/NCT05029882","created_at":"2021-09-01T14:52:59.151Z","updated_at":"2025-02-25T13:53:58.746Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","source_id_and_acronym":"NCT05029882 - M21-404","lead_sponsor":"AbbVie","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • EGFR wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-20"},{"id":"308e274e-e2f7-4972-a5fd-9ed7015b2fc2","acronym":"HERIZON-GEA-01","url":"https://clinicaltrials.gov/study/NCT05152147","created_at":"2021-12-09T18:00:29.644Z","updated_at":"2025-02-25T14:02:38.513Z","phase":"Phase 3","brief_title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","source_id_and_acronym":"NCT05152147 - HERIZON-GEA-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 918","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-19"},{"id":"e1eec305-12a1-4b55-aca1-9621bccaf5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836324","created_at":"2023-05-01T15:04:34.613Z","updated_at":"2025-02-25T14:03:30.395Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05836324","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • BRAF • ER • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA33890"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"3641271b-5a0e-409d-997b-5bc0800249e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056024","created_at":"2023-09-28T15:10:33.953Z","updated_at":"2025-02-25T14:18:20.983Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","source_id_and_acronym":"NCT06056024","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 05/26/2027","primary_completion_date":" 05/26/2027","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2025-02-18"},{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"9e066b71-7f4b-4632-8ecf-e6e2e35a7dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05427487","created_at":"2022-06-22T21:54:15.197Z","updated_at":"2025-02-25T14:08:55.980Z","phase":"Phase 1","brief_title":"Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT05427487","lead_sponsor":"ImmVirx Pty Ltd","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IVX037"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-17"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"99f591b9-7e23-4ea7-a5a0-fe1e2287e1db","acronym":"KEYNOTE-F21","url":"https://clinicaltrials.gov/study/NCT04225117","created_at":"2021-01-18T20:34:06.535Z","updated_at":"2025-02-25T15:18:27.870Z","phase":"Phase 2","brief_title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","source_id_and_acronym":"NCT04225117 - KEYNOTE-F21","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-12"},{"id":"5e06588b-c110-45fd-a169-3b979969f583","acronym":"","url":"https://clinicaltrials.gov/study/NCT05299476","created_at":"2022-03-29T13:52:56.012Z","updated_at":"2025-02-25T15:35:32.829Z","phase":"Phase 2","brief_title":"CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS \u003c 5 GEA","source_id_and_acronym":"NCT05299476","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/16/2022","start_date":" 04/16/2022","primary_txt":" Primary completion: 01/20/2025","primary_completion_date":" 01/20/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-11"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"f5cb8c43-6865-4b75-b3de-bf63f4e8a4e4","acronym":"LEAP-015","url":"https://clinicaltrials.gov/study/NCT04662710","created_at":"2021-01-19T20:42:39.419Z","updated_at":"2025-02-25T13:35:41.688Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","source_id_and_acronym":"NCT04662710 - LEAP-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 10/29/2024","primary_completion_date":" 10/29/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"2c723604-428f-416a-9baf-62d59cb55edd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03821233","created_at":"2021-01-18T18:52:38.184Z","updated_at":"2025-02-25T17:36:12.613Z","phase":"Phase 1","brief_title":"A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers","source_id_and_acronym":"NCT03821233","lead_sponsor":"Zymeworks BC Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zanidatamab zovodotin (ZW49)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 09/27/2024","primary_completion_date":" 09/27/2024","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2025-01-29"},{"id":"1eead00e-edcb-481b-9a08-390ddb32d124","acronym":"CAMILLA","url":"https://clinicaltrials.gov/study/NCT03539822","created_at":"2021-10-27T20:54:20.716Z","updated_at":"2025-02-25T15:07:39.664Z","phase":"Phase 1/2","brief_title":"Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies","source_id_and_acronym":"NCT03539822 - CAMILLA","lead_sponsor":"Anwaar Saeed","biomarkers":" MSI","pipe":" | ","alterations":" RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 10/22/2018","start_date":" 10/22/2018","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-01-14"},{"id":"a286018f-4afb-4b3c-9055-028aded4b971","acronym":"","url":"https://clinicaltrials.gov/study/NCT06687603","created_at":"2025-02-26T07:06:31.824Z","updated_at":"2025-02-26T07:06:31.824Z","phase":"","brief_title":"Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms","source_id_and_acronym":"NCT06687603","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" VIM • CCNA1","pipe":"","alterations":" ","tags":["VIM • CCNA1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/27/2028","primary_completion_date":" 09/27/2028","study_txt":" Completion: 09/27/2029","study_completion_date":" 09/27/2029","last_update_posted":"2025-01-09"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"b8fdfff2-f67c-48fd-9e76-9ef9443b1f2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05480384","created_at":"2022-07-29T15:55:22.037Z","updated_at":"2025-02-25T15:00:32.371Z","phase":"Phase 2","brief_title":"Adjuvant Trastuzumab Deruxtecan (Enhertu) \u0026 Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus \u0026 Gastroesophageal Junction","source_id_and_acronym":"NCT05480384","lead_sponsor":"Brown University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-11-25"},{"id":"34985820-886b-4e61-90e7-8b16e17a8048","acronym":"MEMENTO","url":"https://clinicaltrials.gov/study/NCT06687876","created_at":"2025-02-25T19:17:34.383Z","updated_at":"2025-02-25T19:17:34.383Z","phase":"Phase 2","brief_title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","source_id_and_acronym":"NCT06687876 - MEMENTO","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CD163","pipe":"","alterations":" ","tags":["CD163"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"a35ae63d-7bfa-40bf-b911-fec1b0dea308","acronym":"DECIPHER","url":"https://clinicaltrials.gov/study/NCT05965479","created_at":"2023-07-31T17:08:57.339Z","updated_at":"2025-02-25T15:01:01.413Z","phase":"Phase 2","brief_title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","source_id_and_acronym":"NCT05965479 - DECIPHER","lead_sponsor":"University of Southampton","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/10/2024","start_date":" 04/10/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-11-11"},{"id":"b90611f6-d5aa-4754-9793-ea6b3cb720a3","acronym":"EA2183","url":"https://clinicaltrials.gov/study/NCT04248452","created_at":"2021-01-18T20:38:53.831Z","updated_at":"2025-02-25T16:32:04.439Z","phase":"Phase 3","brief_title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","source_id_and_acronym":"NCT04248452 - EA2183","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-11-05"},{"id":"b7163c5c-0370-418e-8711-fbb409699d7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02962063","created_at":"2021-01-18T14:33:31.039Z","updated_at":"2025-02-25T15:07:20.200Z","phase":"Phase 1/2","brief_title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","source_id_and_acronym":"NCT02962063","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-16"}]